Loading…
Zota Health Care Ltd
NSE: ZOTA INE358U01012 Healthcare Pharma 🔎 Screen
₹3,765 Cr
Market Cap
P/E
PEG
-8.5%
ROCE
-15.0%
ROE
0.39
D/E
0.7%
OPM
-37.5%
% from 52W High
20
α RS
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
Shareholding
About

Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products across boundaries into the semi-regulated and regulated markets of Asian Countries markets of African Countries, Russian Countries & Latin America.

✓ Strengths 1
  • Company is expected to give good quarter
! Concerns 4
  • Stock is trading at 5.43 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -19.9% over last 3 years.
  • Promoter holding has decreased over last 3 years: -18.7%
Key Ratios Snapshot
📊 Sector Averages
📈 Growth Pattern
📊 Quick Scorecard
Loading…
🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
Mixed: Davaindia GMV surged ~87% YoY to ₹164.02 Cr in Q1FY27, but the presentation omits Q1 consolidated P&L and FY26 EBITDA margin remains thin at 4.8%. quarter Investor Presentation One-Pager? Jun 2026
EBITDA Margin
4.8% (FY26)
₹25.98 Cr EBITDA on ₹538.66 Cr revenue; no Q1 margin given
Key Metric
₹164.02 Cr
Q1FY27 Davaindia GMV = COCO ₹115.69 Cr + FOFO ₹48.33 Cr; +86.8% YoY
What Went Right
  • Q1FY27 Davaindia GMV was ₹164.02 Cr, up ~87% YoY from ₹87.78 Cr in Q1FY26.
  • COCO network expanded to 1,855 stores as of Jun 2026, up 88.1% YoY from 986; total stores reached 2,825, up 61.9% YoY.
  • COCO footfall jumped to 44.2 lakhs in Q1FY27 from 23.0 lakhs in Q1FY26 (+92.2%); average wallet spend rose to ₹262 from ₹231 (+13.4%).
  • QIP of ₹350 Cr was completed; company raised EHBC stake to 87.78% and acquired 100% of Curexis, strengthening backward integration and OTC portfolio.
  • Chronic disease products contributed 60% of FY26 Davaindia category mix, supporting repeat purchase and retention (80% repeat customers).
What to Watch
  • No Q1FY27 consolidated revenue, EBITDA, or PAT was provided in the investor presentation, leaving current-quarter profitability unverifiable.
  • FY26 consolidated EBITDA margin is thin at 4.8%; the wide gap versus the 25-30% mature COCO EBITDA claim suggests heavy expansion drag and costs.
  • FOFO average wallet spend fell sequentially to ₹306 in Q1FY27 from ₹309 in Q4FY26 (-1.0%), even as franchisee store count grew to 970.
  • COCO average wallet spend growth (+13.4% YoY) massively lags COCO store growth (+88.1% YoY), indicating new stores are not yet contributing mature per-store economics.
  • The deck provides no explicit path to company-level profitability or same-store sales for the overall mature base, despite claiming faster store rollout.
Investor Lens
The growth thesis remains intact on topline but unproven at the profit line: Q1FY27 Davaindia GMV rose ~87% YoY to ₹164.02 Cr on 2,825 stores, yet the company did not disclose Q1 consolidated revenue, EBITDA, or PAT. FY26 EBITDA margin was only 4.8%, so the gap to the claimed 25-30% mature COCO EBITDA is wide and unexplained by the deck. The next quarter should show whether new COCO stores mature to the stated ~₹2.25 lakh/month by month 10 and whether FOFO wallet spend stabilizes. Watch for consolidated P&L, segment margins, same-store productivity, and OTC contribution from the EHBC/Curexis acquisitions; without margin progress, the rapid store rollout could amplify cash burn.
From investor presentation · AI-generated analysis · Not investment advice
🔒
Premium Feature
Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance
Upgrade to Premium
Already a member? Log in
📉 WEAK Revenue surges 67% but PAT loss widens to ₹44 Cr on negative margins
Revenue
Revenue grew sharply by 67.3% YoY to ₹174.0 Cr, with a modest 6.7% sequential uptick. Top-line momentum is strong, though likely aided by lower-margin segments or one-off volumes.
Profitability
Net loss widened to ₹-44.0 Cr from ₹-14 Cr in the year-ago quarter, with EPS at ₹-12.58. PBT loss of ₹44.0 Cr was aggravated by ₹28 Cr depreciation and ₹6 Cr interest, with negligible tax relief.
Margins
Operating margin turned deeply negative at -7% versus +3.8% in Jun 2025, a steep 10.8 percentage point fall. This reflects cost inflation or expense build-up outpacing revenue growth.
Balance Sheet
Debt-to-equity stands at 0.39, indicating manageable leverage. Elevated depreciation suggests a large fixed-asset base that could support future capacity but weighs on near-term profitability.
Key Risks
Persistent negative operating leverage could deepen losses. High depreciation and interest costs remain fixed burdens. A continued weak margin profile may strain liquidity despite moderate debt levels.
Outlook
While revenue growth is strong, profitability remains under pressure. Margin recovery will hinge on cost discipline and scaling efficiencies in coming quarters.
Generated by AI · Jun 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Documents.

Access concall transcripts, annual reports, credit ratings, and investor presentations.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, SAST trigger, pledge change, concall, and corporate action for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Forensic Report.

A filings-based disclosure review of this company's most recent Annual Report — Accounting Quality Signals, Related Party Disclosures, Auditor Signals, and Governance Watchpoints, generated with your own AI key.

Upgrade to PremiumCreate Free Account

📊 Sector KPIs

Industry-specific KPIs with historical trend — AI-extracted from investor presentations
🔒
Premium Feature
Industry-specific KPIs with historical trend across quarters — AI-extracted from investor presentations
Upgrade to Premium
Already a member? Log in
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including equities and mutual funds, involves inherent risks, including the potential loss of principal. All investments are subject to market fluctuations, regulatory changes, and other risks that may affect their value. Past performance is not indicative of future results. This report is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This report does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a SEBI-registered investment adviser or other qualified financial professional before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities or financial instruments discussed in this report. Any such positions, if material, are disclosed to the best of the author's knowledge and are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company, institution, or third party.

Information Sources:
The analysis and opinions expressed herein are based on publicly available information, including but not limited to company filings with the BSE/NSE, annual reports, management commentary, investor presentations, data from the Reserve Bank of India (RBI), SEBI, industry publications, and other reliable financial data sources. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This report may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. The author does not undertake any obligation to update such statements in the future.

Regulatory Compliance:
This report is intended to comply with the Securities and Exchange Board of India (Research Analysts) Regulations, 2014, as amended, and other applicable Indian laws and regulations.

Limitation of Liability:
The content of this report is provided "as is" without any warranties, express or implied, including accuracy, completeness, merchantability, or fitness for a particular purpose. The author and publisher expressly disclaim any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.